未登录 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab As First-Line Treatment For Endometrial Cancer: Patient-Reported Outcomes In The DUO-E/GOG-3041/ENGOT-EN10 Intent-To-Treat And Mismatch Repair Deficient Populations 度伐利尤单抗联合卡铂/紫杉醇后序贯度伐利尤单抗治疗子宫内膜癌的一线治疗：DUO-E/GOG-3041/ENGOT-EN10研究中的意向性治疗人群和错配修复缺陷人群的患者报告结局 Meyer, Larissa A.; Westin, Shannon N.; Messing, Mark; Hartenbach, Ellen; Carney, Michael; Bradley, William; Sobol, Urszula; Depasquale, Stephen; Agyemang-Prempeh, Kofi; Gil-Martin, Marta; Zagouri, Flora; Bodnar, Lubomir; Palmeiro, Daniela Neves; Wu, Xiaohua; Otero, Marco Antonio Torregroza; Nishikawa, Tadaaki; Kim, Jae-Weon; Donnelly, Conor; Jethoo, Gordhan; Van Nieuwenhuysen, Els 分享 收藏
Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab Plus Olaparib As First-Line Treatment For Endometrial Cancer: Patient-Reported Outcomes In The DUO-E/GOG-3041/ENGOT-EN10 Intent-To-Treat And Mismatch Repair Proficient Populations 度伐利尤单抗联合卡铂/紫杉醇后接度伐利尤单抗联合奥拉帕利作为子宫内膜癌的一线治疗：DUO-E/GOG-3041/ENGOT-EN10研究的全分析集和错配修复功能正常人群的患者报告结局 Van Nieuwenhuysen, Els; Meyer, Larissa; Lucci, Joseph; Berman, Tara; Woliver, Thomas; Gordinier, Mary E.; Burke, James; Mchale, Michael; Galvez-Montosa, Fernando; Zagouri, Flora; Grisan, Karin; Sehouli, Jalid; Palmeiro, Daniela Neves; Wang, Wuliang; Otero, Marco Antonio Torregroza; Nishikawa, Tadaaki; Kim, Jae-Weon; Donnelly, Conor; Rychlik, Greg; Westin, Shannon N. 分享 收藏
Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab With/Without Olaparib In Endometrial Cancer: Exploratory Analyses Of Histology, Biomarker Heterogeneity And Efficacy In The DUO-E Mismatch Repair Proficient Subpopulation Durvalumab联合卡铂/紫杉醇后序贯Durvalumab联合或不联合奥拉帕利在子宫内膜癌中的探索性分析：DUO-E研究错配修复 proficient 亚人群的组织学、生物标志物异质性和疗效分析 Westin, Shannon N.; Moore, Kathleen; Chon, Hye Sook; Pepin, Jessica Thomes; Salinas, Erin A.; Starks, David; Disilvestro, Paul A.; Slomovitz, Brian; Vettus, Elen; Galvez, Fernando; Agyemang-Prempeh, Kofi; Zagouri, Flora; Kim, Jae-Weon; Gao, Qinglei; Contreras-Mejia, Fernando; Melo, Andreia Cristina De; Nishikawa, Tadaaki; Kowgie, Matthew; Iyer, Sonia; Van Nieuwenhuysen, Els 分享 收藏
Detection rate for ESR1 mutations is higher in circulating-tumor-cell-derived genomic DNA than in paired plasma cell-free DNA samples as revealed by ddPCR Smilkou, Stavroula; Ntzifa, Aliki; Tserpeli, Victoria; Balgkouranidou, Ioanna; Papatheodoridi, Alkistis; Razis, Evangelia; Linardou, Helena; Papadimitriou, Christos; Psyrri, Amanda; Zagouri, Flora; Kakolyris, Stylianos; Lianidou, Evi 分享 收藏
分享 收藏
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma Belztifan在晚期透明细胞肾细胞癌患者中的随机II期剂量比较LITESPARK-013研究 Agarwal, N.; Brugarolas, J.; Ghatalia, P.; George, S.; Haanen, J. B.; Gurney, H.; Ravilla, R.; van der Veldt, A.; Beuselinck, B.; Pokataev, I.; Suelmann, B. B. M.; Tuthill, M. H.; Vaena, D.; Zagouri, F.; Wu, J.; Perini, R. F.; Liu, Y.; Merchan, J.; Atkins, M. B. 分享 收藏
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial Pembrolizumab或安慰剂联合放化疗，然后用pembrolizumab或安慰剂治疗新诊断的高危局部晚期宫颈癌 (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): 一项随机，双盲，安慰剂对照的3期试验的总生存期结果 Lorusso, Domenica; Xiang, Yang; Hasegawa, Kosei; Scambia, Giovanni; Leiva, Manuel; Ramos-Elias, Pier; Acevedo, Alejandro; Cvek, Jakub; Randall, Leslie; Gomes, Andrea Juliana Pereira de Santana; Mejia, Fernando Contreras; Helpman, Limor; Akilli, Huseyin; Lee, Jung-Yun; Saevets, Valeriya; Zagouri, Flora; Gilbert, Lucy; Sehouli, Jalid; Tharavichitkul, Ekkasit; Lindemann, Kristina; Colombo, Nicoletta; Chang, Chih-Long; Bednarikova, Marketa; Zhu, Hong; Oaknin, Ana; Christiaens, Melissa; Petru, Edgar; Usami, Tomoka; Liu, Peng; Yamada, Karin; Toker, Sarper; Keefe, Stephen M.; Pignata, Sandro; Duska, Linda R. 分享 收藏
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial Pembrolizumab或安慰剂联合放化疗，然后用Pembrolizumab或安慰剂治疗新诊断的高危局部晚期宫颈癌 (ENGOT-cx11/GOG-3047/KEYNOTE-A18): 一项随机，双盲，3期临床试验 Lorusso, Domenica; Xiang, Yang; Hasegawa, Kosei; Scambia, Giovanni; Leiva, Manuel; Ramos-Elias, Pier; Acevedo, Alejandro; Sukhin, Vladyslav; Cloven, Noelle; Gomes, Andrea J. Pereira de Santana; Mejia, Fernando Contreras; Reiss, Ari; Ayhan, Ali; Lee, Jung-Yun; Saevets, Valeriya; Zagouri, Flora; Gilbert, Lucy; Sehouli, Jalid; Tharavichitkul, Ekkasit; Lindemann, Kristina; Lazzari, Roberta; Chang, Chih-Long; Lampe, Rudolf; Zhu, Hong; Oaknin, Ana; Christiaens, Melissa; Polterauer, Stephan; Usami, Tomoka; Li, Kan; Yamada, Karin; Toker, Sarper; Keefe, Stephen M.; Pignata, Sandro; Duska, Linda R. 分享 收藏
分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
.png){kind=icon}
分享.png){kind=icon}
收藏.png)
LANCET